Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


06.05.2019

3 AJR Am J Roentgenol
1 Am J Clin Oncol
1 BMC Cancer
2 Cancer
1 Clin Cancer Res
4 Eur Urol
2 Int J Radiat Oncol Biol Phys
2 J Nucl Med
2 J Urol
2 Lancet Oncol
2 Nat Rev Urol
4 Oncogene
1 Proc Natl Acad Sci U S A
4 Prostate
1 Urol Int
3 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. FELKER ER, Raman SS, Shakeri S, Mirak SA, et al
    Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer.
    AJR Am J Roentgenol. 2019 Apr 30:1-6. doi: 10.2214/AJR.18.20836.
    PubMed     Text format     Abstract available

  2. CHATTERJEE A, He D, Fan X, Antic T, et al
    Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study.
    AJR Am J Roentgenol. 2019 Apr 30:1-10. doi: 10.2214/AJR.18.20702.
    PubMed     Text format     Abstract available

  3. LAWHN-HEATH C, Flavell RR, Behr SC, Yohannan T, et al
    Single-Center Prospective Evaluation of (68)Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.
    AJR Am J Roentgenol. 2019 Apr 30:1-8. doi: 10.2214/AJR.18.20699.
    PubMed     Text format     Abstract available


    Am J Clin Oncol

  4. TAKU N, Narayan V, Wang X, Vapiwala N, et al
    Prevalence, Predictors, and Implications for Appropriate Use of Active Surveillance Management Among Black Men Diagnosed With Low-risk Prostate Cancer.
    Am J Clin Oncol. 2019 Apr 29. doi: 10.1097/COC.0000000000000547.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. LI T, Sun X, Chen L
    Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function.
    BMC Cancer. 2019;19:87.
    PubMed     Text format     Abstract available


    Cancer

  6. NIK-AHD F, Howard LE, Eisenberg AT, Aronson WJ, et al
    Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.
    Cancer. 2019 Apr 29. doi: 10.1002/cncr.32141.
    PubMed     Text format     Abstract available

  7. JOHNSON DC, Yang JJ, Kwan L, Barsa DE, et al
    Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection.
    Cancer. 2019 May 1. doi: 10.1002/cncr.32170.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  8. KULP SK, Chen CS, Wang DS, Chen CY, et al
    Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
    Clin Cancer Res. 2019;25:2940.
    PubMed     Text format    


    Eur Urol

  9. GNANAPRAGASAM VJ, Barrett T
    The Quest for the Optimal Prostate Biopsy Regime for the 21st Century.
    Eur Urol. 2019;75:741-742.
    PubMed     Text format    

  10. DEVOS G, De Meerleer G, Joniau S
    Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?
    Eur Urol. 2019 Apr 25. pii: S0302-2838(19)30327.
    PubMed     Text format     Abstract available

  11. SHARP A, Welti JC, Lambros MBK, Dolling D, et al
    Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285.
    PubMed     Text format     Abstract available

  12. FLETCHER CE
    The Role of Splicing Regulators in the Emergence of Treatment-induced Neuroendocrine Prostate Cancer: The Next Generation of Drug Targets?
    Eur Urol. 2019 Apr 29. pii: S0302-2838(19)30328.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  13. SANDLER HM
    Responding to Information From Novel Positron Emission Tomography Imaging in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:263-264.
    PubMed     Text format    

  14. MENZEL P, Chang A
    Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;104:261-262.
    PubMed     Text format    


    J Nucl Med

  15. PIRON S, De Man K, Van Laeken N, D'Asseler Y, et al
    Radiation dosimetry and biodistribution of (18)F-PSMA-11 for PET imaging of prostate cancer.
    J Nucl Med. 2019 Apr 26. pii: jnumed.118.225250. doi: 10.2967/jnumed.118.225250.
    PubMed     Text format     Abstract available

  16. HAMMES J, Tager P, Drzezga A
    EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203265. doi: 10.2967/jnumed.117.203265.
    PubMed     Text format     Abstract available


    J Urol

  17. TOSOIAN JJ, George AK
    Editorial Comment.
    J Urol. 2019;201:727.
    PubMed     Text format    

  18. MORTEZAVI A, Krauter J, Gu DA, Sonderer J, et al
    Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound.
    J Urol. 2019 May 1:101097JU0000000000000298. doi: 10.1097/JU.0000000000000298.
    PubMed     Text format     Abstract available


    Lancet Oncol

  19. CURSANO MC, Santini D, Iuliani M, Paganelli G, et al
    Early use of abiraterone and radium-223 in metastatic prostate cancer.
    Lancet Oncol. 2019;20:e228.
    PubMed     Text format    

  20. HINDIE E, Morgat C
    Early use of abiraterone and radium-223 in metastatic prostate cancer.
    Lancet Oncol. 2019;20:e229.
    PubMed     Text format    


    Nat Rev Urol

  21. THOMA C
    Targeting DLL3 in neuroendocrine prostate cancer.
    Nat Rev Urol. 2019 Apr 30. pii: 10.1038/s41585-019-0190.
    PubMed     Text format    

  22. STONE L
    DDR pathway mediates radiosensitization in prostate cancer.
    Nat Rev Urol. 2019 Apr 26. pii: 10.1038/s41585-019-0188.
    PubMed     Text format    


    Oncogene

  23. WANG C, Wang G, Feng X, Shepherd P, et al
    Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
    Oncogene. 2019;38:2451-2463.
    PubMed     Text format     Abstract available

  24. ZHOU PJ, Wang X, An N, Wei L, et al
    Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes.
    Oncogene. 2019;38:2192-2205.
    PubMed     Text format     Abstract available

  25. ZHU S, Tian H, Niu X, Wang J, et al
    Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
    Oncogene. 2019 May 2. pii: 10.1038/s41388-019-0827.
    PubMed     Text format     Abstract available

  26. FLETCHER CE, Sulpice E, Combe S, Shibakawa A, et al
    Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
    Oncogene. 2019 May 1. pii: 10.1038/s41388-019-0823.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  27. GARRIGUE P, Tang J, Ding L, Bouhlel A, et al
    Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors.
    Proc Natl Acad Sci U S A. 2018 Oct 22. pii: 1812938115.
    PubMed     Text format     Abstract available


    Prostate

  28. KURUL NO, Ates F, Yilmaz I, Narli G, et al
    The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
    Prostate. 2019 May 2. doi: 10.1002/pros.23825.
    PubMed     Text format     Abstract available

  29. MCNAMARA MA, Oyekunle T, Chin BB, Oldan J, et al
    Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    Prostate. 2019 May 2. doi: 10.1002/pros.23822.
    PubMed     Text format     Abstract available

  30. KRYVENKO ON, Wang Y, Sadasivan S, Gupta NS, et al
    Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.
    Prostate. 2019 May 2. doi: 10.1002/pros.23820.
    PubMed     Text format     Abstract available

  31. HAN IH, Kim JH, Jang KS, Ryu JS, et al
    Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells.
    Prostate. 2019 May 2. doi: 10.1002/pros.23826.
    PubMed     Text format     Abstract available


    Urol Int

  32. FUJIMOTO N, Shiota M, Tomisaki I, Minato A, et al
    Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer.
    Urol Int. 2019 Apr 30:1-12. doi: 10.1159/000497280.
    PubMed     Text format     Abstract available


    Urology

  33. MAY A, Henke J, Au D, Raza SJ, et al
    National trends in the utilization of androgen deprivation therapy for very low risk prostate cancer.
    Urology. 2019 Apr 29. pii: S0090-4295(19)30366.
    PubMed     Text format     Abstract available

  34. MODI PK, Herrel LA, Kaufman SR, Yan P, et al
    Urologist practice structure and spending for prostate cancer care.
    Urology. 2019 Apr 25. pii: S0090-4295(19)30372.
    PubMed     Text format     Abstract available

  35. PURYSKO AS
    Editorial comment.
    Urology. 2019;123:196-197.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: